News

CVS Health has launched an environmental health impact initiative that aims to support patients with chronic conditions, including chronic obstructive pulmonary disease (COPD), for whom extreme weather events can worsen symptoms. At its onset, the initiative is focusing mainly on extreme heat events, providing excessive heat alerts and…

Exposure to certain air pollution gases — pollutants called volatile organic compounds (VOCs), especially benzene and toluene — significantly increases the risk of chronic obstructive pulmonary disease (COPD) among adults in the U.S., according to a new study. Indeed, one statistical model found COPD risk was three times higher…

People who get more vitamin E from their diet may be less likely to develop chronic obstructive pulmonary disease (COPD), an analysis suggests. Findings indicate that vitamin E supplementation may help in preventing COPD, but more research is needed to confirm this, researchers note. The study “…

Enrollment is now complete in a clinical trial testing RejuvenAir, CSA Medical’s minimally invasive device, in adults with chronic bronchitis — one of the most common forms of chronic obstructive pulmonary disease (COPD). The trial, called SPRAY-CB (NCT03893370), enrolled 210 patients at sites across the U.S. and…

Dupixent (dupilumab) has been approved by the European Commission as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). Specifically, the therapy from Sanofi and Regeneron Pharmaceuticals is now indicated for COPD patients in the European Union who have evidence of type…

The American Lung Association has launched the Wellness Hub, a resource designed to improve the everyday lives of people with chronic obstructive pulmonary disease (COPD) and other lung diseases. Wellness Hub content, including disease-specific online classes, live and on-demand webcasts, and educational resources for improving mental and physical health,…

The U.S. Food and Drug Administration (FDA) has approved Verona Pharma’s ensifentrine as an inhaled maintenance therapy for adults with chronic obstructive pulmonary disease (COPD). The decision makes ensifentrine — to be marketed under the brand name Ohtuvayre — the first therapy with a new mechanism of action…

One in six adults in the U.S. with chronic obstructive pulmonary disease (COPD) didn’t adhere to their medications due to costs, which is associated with a poor prognosis. That’s according to a study that analyzed data from a U.S. survey of adults with COPD between 2013-2020. Patients younger than…

Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe chronic obstructive pulmonary disease (COPD). That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which…

The U.S. Food and Drug Administration (FDA) has delayed by three months its decision about whether to approve Dupixent (dupilumab) as an add-on treatment for certain adults with chronic obstructive pulmonary disease (COPD). A decision is now expected by Sept. 27. An initial call was due at the…